TY - JOUR
T1 - Development of measles virus-based shielded oncolytic vectors
T2 - Suitability of other paramyxovirus glycoproteins
AU - Hudacek, A. W.
AU - Navaratnarajah, C. K.
AU - Cattaneo, R.
N1 - Funding Information:
We thank Dr Christoph Springfeld for providing the TPMV-Fectoantibody and helpful insights into previously attempted envelope exchanges. We thank Dr Stephen Russell for providing the Vero-aHis cell line, and Dr Patricia Devaux for numerous helpful discussions. This work was supported by NIH RO1 CA 139389. The salary of AWH was provided, in part, by the Mayo Graduate School.
PY - 2013/2
Y1 - 2013/2
N2 - Antibody-mediated neutralization may interfere with the efficacy of measles virus (MV) oncolysis. To circumvent vector neutralization, we sought to exchange the envelope glycoproteins, hemagglutinin (H) and fusion (F), with those from the non-crossreactive Tupaia paramyxovirus (TPMV). To sustain efficient particle assembly, we generated hybrid glycoproteins with the MV cytoplasmic tails and the TPMV ectodomains. Hybrid F proteins that partially retained fusion function, and hybrid H proteins that retained fusion support activity, were generated. However, when used in combination, the hybrid proteins did not support membrane fusion. An alternative strategy was developed based on a hybrid F protein and a truncated H protein that supported cell-cell fusion. A hybrid virus expressing these two proteins was rescued, and was able to spread by cell fusion; however, it was only capable of producing minimal amounts of particles. Lack of specific interactions between the matrix and the H protein, in combination with suboptimal F-protein processing and inefficient glycoprotein transport in the rescue cells, accounted for inefficient particle production. Ultimately, this interferes with applications for oncolytic virotherapy. Alternative strategies for the generation of shielded MV are discussed.
AB - Antibody-mediated neutralization may interfere with the efficacy of measles virus (MV) oncolysis. To circumvent vector neutralization, we sought to exchange the envelope glycoproteins, hemagglutinin (H) and fusion (F), with those from the non-crossreactive Tupaia paramyxovirus (TPMV). To sustain efficient particle assembly, we generated hybrid glycoproteins with the MV cytoplasmic tails and the TPMV ectodomains. Hybrid F proteins that partially retained fusion function, and hybrid H proteins that retained fusion support activity, were generated. However, when used in combination, the hybrid proteins did not support membrane fusion. An alternative strategy was developed based on a hybrid F protein and a truncated H protein that supported cell-cell fusion. A hybrid virus expressing these two proteins was rescued, and was able to spread by cell fusion; however, it was only capable of producing minimal amounts of particles. Lack of specific interactions between the matrix and the H protein, in combination with suboptimal F-protein processing and inefficient glycoprotein transport in the rescue cells, accounted for inefficient particle production. Ultimately, this interferes with applications for oncolytic virotherapy. Alternative strategies for the generation of shielded MV are discussed.
KW - Tupaia paramyxovirus
KW - glycoprotein modification
KW - measles virus
KW - vector shielding
UR - http://www.scopus.com/inward/record.url?scp=84874106501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874106501&partnerID=8YFLogxK
U2 - 10.1038/cgt.2012.92
DO - 10.1038/cgt.2012.92
M3 - Article
C2 - 23306608
AN - SCOPUS:84874106501
SN - 0929-1903
VL - 20
SP - 109
EP - 116
JO - Cancer Gene Therapy
JF - Cancer Gene Therapy
IS - 2
ER -